Jefferies Sees Zalviso Upside for AcelRx (ACRX) Following Pain Survey
Get Alerts ACRX Hot Sheet
Rating Summary:
10 Buy, 5 Hold, 1 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 17
Join SI Premium – FREE
Jefferies analyst Biren Amin reiterated a Buy rating and $17 price target on AcelRx Pharmaceuticals (NASDAQ: ACRX) following a physician survey which offered an optimistic upside scenario for Zalviso.
Amin commented, "We recently surveyed 43 physicians which currently prescribe IV patient-controlled analgesia to their post-surgical pain patients to assess the pot'l adoption of new tx over the next 1-2 years. Zalviso captures mkt share of 22% and 26% share in '15 and '16, respectively, and significantly higher than our mkt share assumptions of 1% and 3%, respectively, which drive our risk-adj sales est of $20 million and $65 million."
For an analyst ratings summary and ratings history on AcelRx Pharmaceuticals click here. For more ratings news on AcelRx Pharmaceuticals click here.
Shares of AcelRx Pharmaceuticals closed at $10.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PNC Financial (PNC) PT Lowered to $162 at Jefferies
- Travelers (TRV) PT Lowered to $214 at Morgan Stanley
- Travelers (TRV) PT Lowered to $235 at CFRA
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!